OncoMatch/Clinical Trials/NCT06915753
Safety and Preliminary Anti-Tumor Activity of TYRA-430 in Advanced Hepatocellular Carcinoma and Other Solid Tumors With Activating FGF/FGFR Pathway Aberrations
Is NCT06915753 recruiting? Yes, currently enrolling (Jun 2026). This Phase 1 trial studies TYRA-430 for metastatic hepatocellular carcinoma.
Treatment: TYRA-430 — A Phase 1 study to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamic (PD), and preliminary antitumor activity of TYRA-430 in cancers with FGF/FGFR pathway aberrations, including locally advanced/metastatic hepatocellular carcinoma and other advanced solid tumors.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Hepatocellular Carcinoma
Tumor Agnostic
Biomarker criteria
Required: FGFR3 activating gain-of-function mutation
Must have an eligible activating gain-of-function alteration in the FGFR3 or FGFR4 gene
Required: FGFR4 activating gain-of-function mutation
Must have an eligible activating gain-of-function alteration in the FGFR3 or FGFR4 gene
Required: FGF19 focal amplification
focal amplifications of FGF19
Disease stage
Required: Stage III, IV, BARCELONA CLINIC LIVER CANCER (BCLC) STAGE B THAT IS NOT ELIGIBLE FOR LOCOREGIONAL THERAPY, STAGE C (BCLC)
locally advanced unresectable/metastatic HCC; BCLC stage B that is not eligible for locoregional therapy, or stage C
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Must have received: standard of care
Must have previously received SOC appropriate for their tumor type
Cannot have received: pan-FGFR inhibitor
Prior treatment with pan-FGFR inhibitors
Cannot have received: FGFR4-selective inhibitor
Prior treatment with ... FGFR4-selective inhibitors
Cannot have received: anti-FGFR therapy
Exception: Discontinued due to significant toxicity, defined as hepatotoxicity ≥ Grade 3 or any Grade 4 toxicity
Participant discontinued a prior anti-FGFR therapy due to significant toxicity, defined as hepatotoxicity ≥ Grade 3 or any Grade 4 toxicity according to CTCAE v5.0
Lab requirements
Liver function
child-pugh score class a
Cardiac function
no uncontrolled cardiovascular disease
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- USC Norris Comprehensive Cancer Center · Los Angeles, California
- UCSF Medical Center at Mount Zion · San Francisco, California
- Stanford Cancer Institute · Stanford, California
- The University of Kansas Medical Center · Westwood, Kansas
- John Hopkins University · Baltimore, Maryland
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT06915753 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior pan-FGFR inhibitor, FGFR4-selective inhibitor, anti-FGFR therapy disqualifies patients from enrollment.
Does this trial require FGFR3?
Yes, FGFR3 activating gain-of-function mutation is a required biomarker for enrollment.
Does this trial require FGFR4?
Yes, FGFR4 activating gain-of-function mutation is a required biomarker for enrollment.
Does this trial require FGF19?
Yes, FGF19 focal amplification is a required biomarker for enrollment.
What disease stage is eligible?
Stage III or IV or BARCELONA CLINIC LIVER CANCER (BCLC) STAGE B THAT IS NOT ELIGIBLE FOR LOCOREGIONAL THERAPY or STAGE C is required.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages